These complexities include the heterogeneous nature of the cancer and the potential for BCMA evasion or shedding, which can be tackled through innovative CAR designs, such as dual or multitarget CAR T-cells [71, 104] (Table 2). This evidence concerns the gene TNFRSF17 and cancer.